Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Shares Outstanding (Weighted Average) (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $137.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 23.42% year-over-year to $137.7 million, compared with a TTM value of $137.7 million through Dec 2025, up 23.42%, and an annual FY2025 reading of $137.7 million, up 23.42% over the prior year.
  • Shares Outstanding (Weighted Average) was $137.7 million for Q4 2025 at Avidity Biosciences, up from $132.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $137.7 million in Q4 2025 and bottomed at $37.5 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $80.3 million, with a median of $72.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) soared 1218.84% in 2021, then grew 7.22% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $41.4 million in 2021, then rose by 25.91% to $52.2 million in 2022, then surged by 39.97% to $73.0 million in 2023, then surged by 52.83% to $111.6 million in 2024, then grew by 23.42% to $137.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for RNA at $137.7 million in Q4 2025, $132.3 million in Q3 2025, and $129.6 million in Q2 2025.